This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
We've shown that we can make a major contribution to a national effort that’s much larger than just cardiothoracic surgery.” With the enrollment of more than 2,000 patients in randomized trials and more than 14,000 patients in observational studies over the years, CTSN is among the top performers of NHLBI- and NIH-funded research groups.
This fellowship also will allow Dr. Fiedler and Dr. Folesani to learn novel techniques, adapt innovative technology, and receive training from expert mentors who are dedicated to the highest standards of cardiothoracic surgery. Applications for the 2023 TSF/FFF Fellowship will open this summer. For more information, visit sts.org.
The researchers reported that 28 patients (93.3%) survived VV-ECMO. A 6-minute walk test was performed in 16 patients (59.3%) with a median value of 350 meters, which the researchers called “encouraging.” “We These patients were hospitalized for a median of 45 days and supported on VV-ECMO for a median of 19 days.
Bucshon and Schrier on this important bill which will not only have a measurable impact on clinical research, but also make a difference in cardiovascular clinicians’ efforts to transform cardiovascular care and improve heart health.” The ACC looks forward to working with Reps. Learn more at sts.org. For more, visit acc.org.
Press Release ERAS Program Expedites Recovery for Congenital Heart Surgery Patients January 30, 2021 jbagley Wed, 01/27/2021 - 16:12 Study shows multidisciplinary pediatric care improves patient outcomes and experiences **A recorded press briefing featuring this research is available.**
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content